GYRE THERAPEUTICS, INC. (GYRE)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, GYRE THERAPEUTICS, INC. reported revenue of $116.59M, up 10.2% from the prior year. The company was profitable, with a net margin of 8.5%. It held $166.13M in total assets against $23.85M in total liabilities.
Key ratios (FY2025)
9.9%
Operating margin
8.5%
Net margin
9.3%
Return on equity
+10.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116.59M | $105.76M | $113.45M | $102.29M | $7.34M | $20.95M | — | $6.0K | $1.02M | — |
| Cost of Revenue | $5.42M | $3.88M | $4.64M | $4.79M | — | — | — | — | — | — |
| Gross Profit | — | $101.87M | $108.81M | $97.50M | — | — | — | — | — | — |
| Operating Income | $11.49M | $16.16M | -$67.23M | $9.20M | -$87.89M | -$57.37M | -$57.28M | -$33.82M | -$21.82M | -$20.42M |
| Net Income | $9.88M | $17.90M | -$85.48M | $4.31M | -$87.93M | -$56.24M | -$55.18M | -$30.05M | -$21.56M | -$16.95M |
| EPS (Diluted) | $0.02 | $0.05 | $-1.41 | $0.03 | $-2.87 | — | — | — | — | — |
| Total Assets | $166.13M | $125.41M | $116.54M | $84.75M | $55.66M | $94.85M | $98.55M | $124.92M | $39.51M | $38.09M |
| Total Liabilities | $23.85M | $27.00M | $38.06M | $12.54M | $14.57M | $18.78M | $30.22M | $4.97M | $8.74M | $22.02M |
| Shareholders' Equity | $106.03M | $63.32M | -$15.83M | $42.52M | $41.09M | $76.07M | $68.34M | $119.94M | $30.77M | $16.07M |
| Cash & Equivalents | $37.07M | $11.81M | $33.51M | $25.18M | $44.35M | $30.36M | $15.37M | $31.21M | $14.47M | $10.26M |
| Operating Cash Flow | $1.01M | -$3.64M | $25.89M | $10.68M | -$83.75M | -$55.05M | -$43.61M | -$28.55M | -$19.94M | — |
| Capital Expenditures | $1.19M | $2.31M | $8.52M | $4.99M | $839.0K | — | $64.0K | $376.0K | $23.0K | $468.0K |
| Shares Outstanding | 91.31M | 86.31M | 76.60M | 63.59M | 31.41M | 22.10M | 12.04M | 11.95M | 6.08M | 801.8K |
| Dividends Per Share | — | — | — | $0.24 | — | — | — | — | — | — |